- Home
- SENEA vs ARVN Comparison
SENEA vs ARVN Comparison
Compare SENEA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEA | ARVN |
|---|---|---|
| Founded | 1949 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 817.6M | 781.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SENEA | ARVN |
|---|---|---|
| Price | $123.99 | $11.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $15.15 |
| AVG Volume (30 Days) | 45.0K | ★ 721.1K |
| Earning Date | 02-05-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.79 | N/A |
| EPS | ★ 8.61 | N/A |
| Revenue | ★ $1,606,175,000.00 | $312,300,000.00 |
| Revenue This Year | N/A | $10.55 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | 8.33 | ★ 93.86 |
| 52 Week Low | $77.08 | $5.90 |
| 52 Week High | $134.14 | $20.38 |
Technical Indicators
Market Signals| Indicator | SENEA | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 37.51 |
| Support Level | $116.82 | $11.38 |
| Resistance Level | $128.64 | $14.00 |
| Average True Range (ATR) | 5.35 | 0.77 |
| MACD | 0.60 | -0.25 |
| Stochastic Oscillator | 49.21 | 4.53 |
Price Performance
Historical ComparisonAbout SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.